Anesthesiology and Intensive Care, Department of Clinical Sciences Lund, Helsingborg Hospital, Lund University, Helsingborg, Sweden
Anesthesiology and Intensive Care, Department of Clinical Sciences Lund, Helsingborg Hospital, Lund University, Helsingborg, Sweden.
BMJ Open. 2023 Feb 28;13(2):e065392. doi: 10.1136/bmjopen-2022-065392.
Administration of large volumes of fluids is associated with poor outcome in septic shock. Recent data suggest that non-resuscitation fluids are the major source of fluids in the intensive care unit (ICU) patients suffering from septic shock. The present trial is designed to test the hypothesis that a protocol targeting this source of fluids can reduce fluid administration compared with usual care.
The design will be a multicentre, randomised, feasibility trial. Adult patients admitted to ICUs with septic shock will be randomised within 12 hours of admission to receive non-resuscitation fluids either according to a restrictive protocol or to receive usual care. The healthcare providers involved in the care of participants will not be blinded. The participants, outcome assessors at the 6-month follow-up and statisticians will be blinded. Primary outcome will be litres of fluids administered within 3 days of randomisation. Secondary outcomes will be proportion of randomised participants with outcome data on all-cause mortality; days alive and free of mechanical ventilation within 90 days of inclusion; any acute kidney injury and ischaemic events in the ICU (cerebral, cardiac, intestinal or limb ischaemia); proportion of surviving randomised patients who were assessed by European Quality of Life 5-Dimensions 5-Level questionnaire and Montreal Cognitive Assessment; proportion of all eligible patients who were randomised and proportion of participants experiencing at least one protocol violation.
Ethics approval has been obtained in Sweden. Results of the primary and secondary outcomes will be submitted for publication in a peer-reviewed journal.
NCT05249088.
在感染性休克患者中,大量输液与不良预后相关。最近的数据表明,非复苏液是重症监护病房(ICU)中感染性休克患者液体的主要来源。本试验旨在检验以下假设,即针对该液体来源的方案可与常规治疗相比减少液体输注。
这将是一项多中心、随机、可行性试验。在入院后 12 小时内,将入住 ICU 的感染性休克成年患者随机分为两组,分别接受限制复苏液或常规治疗。参与患者护理的医护人员不会被设盲。参与者、6 个月随访时的结局评估者和统计人员将被设盲。主要结局为随机分组后 3 天内输注的液体量。次要结局将包括:所有原因死亡率的随机分组参与者的结局数据比例;纳入后 90 天内存活且无机械通气天数;ICU 中的任何急性肾损伤和缺血事件(脑、心、肠或肢体缺血);接受欧洲生活质量 5 维度 5 级问卷和蒙特利尔认知评估评估的随机分组存活患者比例;所有合格患者的随机分组比例和至少经历一次方案违反的参与者比例。
瑞典已获得伦理批准。将主要和次要结局的结果提交给同行评议期刊发表。
NCT05249088。